PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.
PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.
复制标题
DOI：
10.2174/1871530311006040367
复制
发表时间：
2010-12
期刊：
影响因子：
--
通讯作者：
Sun Z
中科院分区：
文献类型：
--
作者：
Kwon MJ;Wang R;Ma J;Sun Z
蛋白激酶C θ（PKC-θ）是介导T细胞受体（TCR）信号的关键激酶。由T细胞受体（TCR）接合激活的PKC-θ易位至免疫突触并调节转录因子NFκB、AP-1和NFAT的激活。然后这些转录因子激活靶基因，如IL-2。PKC-θ缺陷的T细胞在体外和体内均表现出T细胞活化、存活、活化诱导的细胞死亡和向炎性T细胞（如Th 2和Th 17细胞）分化的缺陷。由于这些效应T辅助细胞负责介导自身免疫，因此选择性抑制PKC-θ被认为是预防自身免疫性疾病和同种异体移植排斥的治疗方法。
Protein kinase C theta (PKC-θ) is a key kinase in mediating T cell receptor (TCR) signals. PKC-θ activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NFκB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC-θ display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, such as Th2 and Th17 cells both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC-θ is considered a treatment for prevention of autoimmune diseases and allograft rejection.